Tag Archives: Ipsen

October, 2017

18 October
Ipsen and Exelixis’ Cabozantinib Meets Primary Endpoint in Phase 3 Hepatocellular Carcinoma Trial

PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with …
Share

19 June
FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults

BASKING RIDGE, N.J.–(BUSINESS WIRE)–Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport®(abobotulinumtoxinA) for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) …
Share

9 January
Ipsen to Acquire Oncology Assets from Merrimack

CAMBRIDGE, Mass., Jan. 8, 2017 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) (“Merrimack” or the “Company”) today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen (Euronext: IPN; ADR: IPSEY) for a transaction valued at up to $1.025 billion, plus up to $33 million in …
Share

16 April
Study Results Lead Active Biotech and Ipsen to Discontinue Development of their Prostate Cancer Program

Today, Active Biotech and Ipsen announced their decision to discontinue development of their investigational prostate cancer drug after it failed to improve overall survival in a late-stage study. The companies announced top line results of the Phase III 10TASQ10 study evaluating tasquinimod in patients with metastatic castration resistant prostate cancer …
Share